| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6110747 | Pancreatology | 2015 | 8 Pages |
Abstract
This SRCPCX model retains major histopathological and immunohistochemical characteristics of the original tumour and when a combination of measures is used, enables early assessment of tumour sensitivity to gemcitabine in pancreatic cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Aiqun Xue, Sohel M. Julovi, Thomas J. Hugh, Jaswinder S. Samra, Matthew H.F. Wong, Anthony J. Gill, Christopher W. Toon, Ross C. Smith,